142 related articles for article (PubMed ID: 36647745)
1. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226).
Bergqvist M; Nordmark A; Williams A; Paoletti C; Barlow W; Cobain EF; Mehta RS; Gralow JR; Hortobagyi GN; Albain KS; Pusztai L; Sharma P; Godwin AK; Thompson AM; Hayes DF; Rae JM
Biomarkers; 2023 May; 28(3):313-322. PubMed ID: 36647745
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
Paoletti C; Barlow WE; Cobain EF; Bergqvist M; Mehta RS; Gralow JR; Hortobagyi GN; Albain KS; Pusztai L; Sharma P; Godwin AK; Thompson AM; Hayes DF; Rae JM
Clin Cancer Res; 2021 Nov; 27(22):6115-6123. PubMed ID: 34521624
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson JJ; Guzauskas GF; Dann RA; Ramsey SD
J Med Econ; 2021; 24(1):1309-1317. PubMed ID: 34763605
[TBL] [Abstract][Full Text] [Related]
4. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Malorni L; Tyekucheva S; Hilbers FS; Ignatiadis M; Neven P; Colleoni M; Henry S; Ballestrero A; Bonetti A; Jerusalem G; Papadimitriou K; Bernardo A; Seles E; Duhoux FP; MacPherson IR; Thomson A; Davies DM; Bergqvist M; Migliaccio I; Gebhart G; Zoppoli G; Bliss JM; Benelli M; McCartney A; Kammler R; De Swert H; Ruepp B; Fumagalli D; Maibach R; Cameron D; Loi S; Piccart M; Regan MM; ;
Eur J Cancer; 2022 Mar; 164():39-51. PubMed ID: 35172272
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
McCartney A; Biagioni C; Schiavon G; Bergqvist M; Mattsson K; Migliaccio I; Benelli M; Romagnoli D; Bonechi M; Boccalini G; Pestrin M; Galardi F; De Luca F; Biganzoli L; Piccart M; Gradishar WJ; Chia S; Di Leo A; Malorni L
Eur J Cancer; 2019 Jun; 114():55-66. PubMed ID: 31059974
[TBL] [Abstract][Full Text] [Related]
7. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A; Bonechi M; De Luca F; Biagioni C; Curigliano G; Moretti E; Minisini AM; Bergqvist M; Benelli M; Migliaccio I; Galardi F; Risi E; De Santo I; Romagnoli D; Biganzoli L; Di Leo A; Malorni L
Clin Cancer Res; 2020 May; 26(9):2131-2139. PubMed ID: 31937617
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni L; Bianchini G; Caputo R; Zambelli A; Puglisi F; Bianchi GV; Del Mastro L; Paris I; Montemurro F; Allegrini G; Colleoni M; Tamberi S; Zamagni C; Cazzaniga ME; Orditura M; Guarneri V; Castelletti D; Benelli M; Di Marino M; Arpino G; De Laurentiis M
Eur J Cancer; 2023 Jun; 186():1-11. PubMed ID: 37003098
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
10. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
11. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
[TBL] [Abstract][Full Text] [Related]
12. Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study.
Asplund E; Bergqvist M; Krook M; Löhr JM
Scand J Gastroenterol; 2023; 58(9):1044-1048. PubMed ID: 37038772
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
14. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
[TBL] [Abstract][Full Text] [Related]
17. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
19. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
20. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]